In updated analysis , median survival time was 17.7 ( IP ) versus 15.0 months ( AP ; HR , 1.43 ; 95 % CI , 1.10 to 1.85 ) , median progression-free survival was 5.6 ( IP ) versus 5.1 months ( AP ; HR , 1.42 ; 95 % CI , 1.16 to 1.73 ) , and response rate was 72.3 % ( IP ) versus 77.9 % ( AP ; P = .33 ) .